Long‐term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field‐directed treatment for actinic keratosis

Publisher： John Wiley & Sons Inc

E-ISSN： 1468-3083|29|9|1840-1842

ISSN： 0926-9959

Source： JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol.29, Iss.9, 2015-09, pp. : 1840-1842

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy of imiquimod 3.75% from Lmax according to the number of actinic keratosis lesions

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 12, 2015-12 ,pp. : 2470-2473

John Wiley & Sons Inc

Access to resources Recommend Favorite

Physician perceptions and experience of current treatment in actinic keratosis

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 2, 2015-02 ,pp. : 298-306

John Wiley & Sons Inc

Access to resources Recommend Favorite

Online conferences for guidelines

By  

JOURNAL OF EVALUATION IN CLINICAL PRACTICE (ELECTRONIC), Vol. 20, Iss. 6, 2014-12 ,pp. : 853-856

John Wiley & Sons Inc

Access to resources Recommend Favorite

A randomized trial comparing simultaneous vs. sequential field treatment of actinic keratosis with ingenol mebutate on two separate areas of the head and body

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 11, 2015-11 ,pp. : 2192-2198

John Wiley & Sons Inc

Access to resources Recommend Favorite

A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosis

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 54, Iss. 5, 2015-05 ,pp. : 509-515

John Wiley & Sons Inc

Access to resources Recommend Favorite